Argentiere Capital’s Bristol-Myers Squibb BMY Stock Holding History

Argentiere Capital’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-1,150,000	Closed	-$1.9M	–	49
2017 Q1	$1.9M	Buy	+1,150,000	New	+$63.1M	0.76%	39
2016 Q3	–	Sell	-150,000	Closed	-$435K	–	54
2016 Q2	$435K	Sell	150,000 -25,000	-14%	-$1.77M	0.34%	37
2016 Q1	$254K	Buy	+175,000	New	+$11M	0.15%	57

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Argentiere Capital's BMY Position: Q2 2017 in Review

Argentiere Capital sold out of Bristol-Myers Squibb (BMY) in Q2 2017, closing a stake of 87,880 shares — an estimated $4.78M sold.

Argentiere Capital first reported a position in BMY in Q1 2017 and held it in 1 quarter. The position peaked at $4.78M in Q1 2017. 1,595 funds tracked by Wall St. Rank hold BMY as of Q2 2017.

Argentiere Capital reported no remaining Bristol-Myers Squibb position as of Q2 2017 after selling out during the quarter.
Argentiere Capital sold 87,880 Bristol-Myers Squibb shares in Q2 2017, an estimated $4.78M.
Argentiere Capital first reported a position in Bristol-Myers Squibb in Q1 2017 and held it in 1 quarter.
Argentiere Capital's Bristol-Myers Squibb position peaked at $4.78M in Q1 2017.
1,595 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2017.

Based on Argentiere Capital's 13F filing for Q2 2017, filed 14 Aug 2017.